Test/dosage | Sensitivity | Specificity | Main references |
---|---|---|---|
Detection of haematuria using a reactive test strip | 46 to 74% for one test, If test repeated over several days: 90 to 95% | 51 to 84% | |
Urinary cytology | ▪ For all tumour grades and stages: 44% [CI 95%, 38–51] [203] | ▪ For all tumour grades and stages: 96% [CI 95%, 94–98][203] | |
â–ª For Carcinoma in situ (Cis) 70 to 90% | â–ª For Cis: 90% | ||
NMP22BC test | ▪ For all tumour grades and stages: 65% [CI 95%, 50–80] [203] | ▪ For all tumour grades and stages: 81% [CI 95%, 50–85] [203] | |
- NMIBC: 81.8% | |||
- MIBC: 57.1% | |||
- Grade G1: 83.9% | |||
- Grade G3: 62.5% | |||
Fluorescence immunocytochemistry (ImmunoCyt™/uCyt + ™) | ▪ For all tumour grades and stages: 84% [CI 95%, 77–91] [203] | ▪ For all tumour grades and stages: 75% [CI 95%, 68–83] [203] | |
FISH (Fluorescence In Situ Hybridisation) UroVysion™ Kit | ▪ For all tumour grades and stages: 76% [CI 95%, 65–84] [203] | ▪ For all tumour grades and stages: 75% [CI 95%, 78–92] [203] | |
â–ª For Cis and G3: >95% |